Cartesian Therapeutics Files 8-K: Regulation FD Disclosure

Ticker: RNAC · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1453687

Cartesian Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCartesian Therapeutics, Inc. (RNAC)
Form Type8-K
Filed DateApr 9, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials

TL;DR

Cartesian Therapeutics filed an 8-K with updates and financial info.

AI Summary

On April 8, 2024, Cartesian Therapeutics, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. The company's principal executive offices are located at 704 Quince Orchard Road, Gaithersburg, MD 20878.

Why It Matters

This 8-K filing provides important updates and disclosures from Cartesian Therapeutics, Inc. to the public, ensuring transparency in its operations and financial reporting.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for disclosures and financial statements, not indicating any immediate operational or financial distress.

Key Players & Entities

  • Cartesian Therapeutics, Inc. (company) — Registrant
  • April 8, 2024 (date) — Date of earliest event reported
  • 704 Quince Orchard Road, Gaithersburg, MD 20878 (location) — Address of principal executive offices
  • 001-37798 (company_id) — Commission File Number
  • 26-1622110 (company_id) — IRS Employer Identification No.

FAQ

What is the primary purpose of this 8-K filing by Cartesian Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and other events, along with financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on April 8, 2024.

Where are Cartesian Therapeutics, Inc.'s principal executive offices located?

Cartesian Therapeutics, Inc.'s principal executive offices are located at 704 Quince Orchard Road, Gaithersburg, MD 20878.

What is the Commission File Number for Cartesian Therapeutics, Inc.?

The Commission File Number for Cartesian Therapeutics, Inc. is 001-37798.

What is the IRS Employer Identification Number for Cartesian Therapeutics, Inc.?

The IRS Employer Identification Number for Cartesian Therapeutics, Inc. is 26-1622110.

Filing Stats: 689 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-04-09 07:00:05

Key Financial Figures

  • $0.0001 — ich registered Common Stock (Par Value $0.0001) RNAC The Nasdaq Stock Market LLC Ind

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Cartesian Therapeutics, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1, except as required by law.

01 Other Events

Item 8.01 Other Events. As previously disclosed, at a special meeting of stockholders held on March 27, 2024, the stockholders of the Company approved the issuance of shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), upon conversion of the Company's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"). The Automatic Conversion (as defined in the Certificate of Designation) of the Series A Preferred Stock occurred on April 8, 2024 at 5:00 p.m. Eastern Time pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock, as amended (as so amended, the "Certificate of Designation"), of the Series A Preferred Stock. Following the Automatic Conversion of the Series A Preferred Stock, there are 17,779,787 shares of the Company's Common Stock issued and outstanding.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Corporate slide presentation of Cartesian Therapeutics, Inc. dated April 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARTESIAN THERAPEUTICS, INC. Date: April 9, 2024 By: /s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.